This is a prospective, multicentric, european registry of patients with infective endocarditis undergoing cardiac surgery. Patient demographics, clinical data and laboratory values will be collected, as well as treatment outcomes at day 30, day 90 and 1-5 years after the intervention.
Infective endocarditis (IE) is now a relatively rare but worldwide disease (3-10 IE/100000 population/year) with increasing incidence especially in the Western world. IE is still associated with high morbidity and mortality, prolonged hospital stay, high risk of reinfection, significantly worsened prognosis for patients, substantially reduced quality of life, and in any case represents a major financial burden for the respective healthcare systems \[1-11\]. Patients who need to undergo cardiac surgery due to infective endocarditis (IE) are heterogeneous and present with a persistently high perioperative morbidity and mortality rate. Despite optimal and individualized perioperative management strategies, perioperative complications such as heart failure, systemic inflammatory response, vasoplegia, and sepsis is still the main reason for adverse outcomes following cardiac surgery. The present European, multicenter IE registry (Surgical RegistRy of infective ENDocarditis in EuRope - SURRENDER) was initiated and established to record and appropriately analyze current surgical treatment options and perioperative adjunctive treatment strategies, as well as short- and long-term patient outcomes.
Study Type
OBSERVATIONAL
Enrollment
10,000
Patients with infective endocarditis undergoing open heart surgery
Department of Cardiac Surgery, Hospital Nürnberg, Paracelsus Medical University
Nuremberg, Bavaria, Germany
University Hospital Essen, Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Center, University Duisburg-Essen
Essen, Germany
In-hospital mortality (all cause)
Overall mortality rate in-hospital, at day 30 or during index hospitalization
Time frame: 30 days or during index hospitalization
Mortality at long-term follow-up
at 1 to 5 years post-surgery
Time frame: 1 to 5 years
MACCE
Major adverse cardiac and cerebrovascular event rate at day 30 or during index hospitalization. Composite of 1.) Cardiac events: (postoperative myocardial infarction, CPR, LCOS/heart failure, repeat cardiac surgery) and/or cerebrovascular events (postoperative stroke, TIA, intracranial hemorrhage)
Time frame: 30 days or during index hospitalization
MACCE at long term follow-up
Major adverse cardiac and cerebrovascular event rate at 1 to 5 years post-surgery
Time frame: 1 to 5 years
Sepsis accociated mortatilty
Sepsis accociated mortatilty at day 30 or during index hospitalization
Time frame: 30 days or during index hospitalization
Post-operative sepsis
Sepsis at day 30 or during index hospitalization
Time frame: 30 days or during index hospitalization
Vasoactive inotropic score
The sum of maximum dose rates of inotropes and/or vasopressor medications administered the first 72h post-surgery
Time frame: < 72h post-surgery
Mechanical ventilation time
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Duration of postoperative invasive/mechanical ventilation post-surgery
Time frame: 30 days or during index hospitalization
Readmission due to IE recurrence
Recurrence of infective endocarditis after 30 days to 1 year post-surgery
Time frame: 30 days to 1 year post-surgery
Renal failure
Occurence of renal failure (KDIGO criteria)
Time frame: 30 days or during index hospitalization
Dialysis (RRT post-surgery)
Occurence of renal failure requiring renal replacement therapy
Time frame: 30 days or during index hospitalization